Qiagen N.V.

As of June 30, 2026, QIAGEN NV carries a market capitalization of 7.15B, placing it among publicly traded companies globally. Its enterprise value stands at 7.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

QIAGEN NV's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, QIAGEN NV has 206.50M shares outstanding.

As of June 30, 2026, QIAGEN NV trades at a trailing price-to-earnings ratio of 19.93. The price-to-sales ratio is 3.88, and the price-to-book ratio stands at 2.43.

As of June 30, 2026, QIAGEN NV trades at an EV/EBITDA multiple of 13.92 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.24 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. QIAGEN NV trades at an EV/FCF ratio of 18.95, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 7.89B versus a market cap of 7.15B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, QIAGEN NV maintains a current ratio of 2.85, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 48.95, indicating elevated leverage, while an interest coverage ratio of 16.42 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, QIAGEN NV posted a return on equity (ROE) of 11.93, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.97 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.99, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.93, useful for judging operating efficiency across full business cycles. The company generates approximately 323,570.68 in revenue per employee across its workforce of 5,681.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.63 indicates how many times QIAGEN NV sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, QIAGEN NV recorded 45.96M in income tax expense. That works out to an effective tax rate of 11.37, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 404.24M, leaving 358.27M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, QIAGEN NV's stock has gained approximately 1.80% over the past 52 weeks. The 50-day moving average sits at 38.46, while the 200-day moving average is 36.47.

Over the twelve months ended June 30, 2026, QIAGEN NV generated 1.84B in revenue and converted that into 358.27M in net income, yielding earnings per share of 1.72. EBITDA reached 566.80M, while operating income came in at 452.22M.

As of June 30, 2026, QIAGEN NV holds 694.55M in cash and equivalents against 1.44B in total debt, resulting in a net debt position of 765.99M. Total book value stands at 2.94B, with working capital of 941.11M providing operational flexibility.

QIAGEN NV produced 572.86M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -187.20M in capital expenditures, free cash flow totaled 385.65M - equivalent to 1.87 per share.

Over the twelve months ended June 30, 2026, QIAGEN NV posted a gross margin of 62.20, reflecting its pricing power and cost economics. The operating margin of 24.60 and net profit margin of 19.49 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, QIAGEN NV paid dividends of 0.00 per share. The dividend payout ratio of 0.00 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.36, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.61, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to QIAGEN NV shareholders.

QIAGEN NV's most recent stock split took place on January 8, 2026 with a 20:19 split ratio.

As of June 30, 2026, QIAGEN NV has an Altman Z-Score of 5.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.